期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

小分子酪氨酸激酶抑制剂治疗非小细胞肺癌研究现状

小分子酪氨酸激酶抑制剂治疗非小细胞肺癌研究现状
原文传递
导出
摘要 肺癌在全世界是癌症死亡的首因,其中80%为非小细胞肺癌(NSCLC)。手术仍然是唯一可以治愈NSCLC的方法,但大部分NSCLC患者确诊时已属晚期,失去手术机会。晚期NSCLC传统的一线治疗主要是铂类为基础的两药联合化疗或化疗联合放疗。
作者 郝建东 韩福才
机构地区 山西医科大学第二医院
出处 《中国实用内科杂志》 CAS CSCD 北大核心 2008年第S2期137-141,共5页 Chinese Journal of Practical Internal Medicine
关键词 非小细胞肺癌 酪氨酸激酶抑制剂 埃罗替尼 吉非替尼 non-small cell lung cancer tyrosine kinase inhibitors erlotinib gefitinib
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1徐建明,宋三泰.表皮生长因子受体酪氨酸激酶靶向药物与化疗联合应用的合理设计[J].中华肿瘤杂志,2004,26(6):321-323. 被引量：20
  • 2Bezjak A,,Shepherd F,Tu D,et al.Symptone response in non-small cell lung cancer(NSCLC)patients treated with erlo-tinib:quality of life analysis of the NCICCTG BR.21trial. . 2005
  • 3Wacker B,,Nagrani T,Weinberg J,et al.Correlation between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies. Clinical Cancer Research . 2007
  • 4Tiseo M,Gridelli C,Cascinu S,et al.An expanded access pro-gram of erlotinib(Tarceva)in patients with advanced non-small cell lung cancer(NSCLC):Data report from Italy.. . 2008
  • 5Lee JS,,Ignacio J,Yu C,et al.FAST-ACT:A phase II ran-domized double-blind trial of sequential erlotinib and chemo-therapy as first-line treatment in patients(pts)with stage IIIB/IV non-small cell lung cancer(NSCLC). Proceedings of the American Society of Clinical Oncology . 2008
  • 6Rosell R,Robinet G,Szczesna A,et al.Randomized phase study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advancednon small cell lung cancer. Annals of Oncology . 2008
  • 7Shepherd FA,Rodrigues PJ,Ciuleanu T,et al.Erlotinib in previ-ously treated non-small-cell lung cancer. The New England Journal of Medicine . 2005
  • 8Tsao,MS,Sakurada,A,Cutz,JC,Zhu,CQ,Kamel-Reid,S,Squire,J,Lorimer,I,Zhang,T,Liu,N,Daneshmand,M,Marrano,P,da Cunha Santos,G,Lagarde,A,Richardson,F,Seymour,L,Whitehead,M,Ding,K,Pater,J,Shepherd,FA.Erlotinib in lung cancer—molecular and clinical predictors of outcome. The New England Journal of Medicine . 2005
  • 9Ahn MJ,Park BB,Ahn JS,et al.Are there any ethnic differ-ences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer-. Clinical Cancer Research . 2008
  • 10Riely,GJ,Pao,W,Pham,D,Li,AR,Rizvi,N,Venkatraman,ES,Zakowski,MF,Kris,MG,Ladanyi,M,Miller,VA.Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and 21 mutations treated with gefitinib or erlotinib. Clinical Cancer Research . 2006

二级参考文献20

  • 1宋三泰,汤仲明.重视乳癌ER及内分泌治疗的临床研究[J].中华肿瘤杂志,1993,15(2):83-85. 被引量：10
  • 2Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol, 2002,20(18 Suppl):1S-13S.
  • 3Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res, 2001,7:2958-2970.
  • 4Baselga J. The EGFR as a target for anticancer therapy-focus on cetuximab. Eur J Cancer, 2001,37( Suppl 4):S16-S22.
  • 5Ciardiello F, Caputo R, Bianco R, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res, 2001,7:1459-1465.
  • 6Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol, 2003,21:2237-2246.
  • 7Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol, 2004,22:785-794.
  • 8Herbst RS. ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs, 2002,11:837-849.
  • 9Sewell JM, Macleod KG, Ritchie A, et al. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (''Iressa'').Br J Cancer, 2002,86:456-462.
  • 10Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res,1999,5:909-916.

共引文献19

中国实用内科杂志
2008年 第S2期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部